A Phase II Study of Regorafenib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

Full Title

Purpose

Adenoid cystic carcinoma is a rare type of salivary gland cancer. In this study, researchers are assessing the safety and effectiveness of the drug regorafenib in patients with adenoid cystic carcinoma that has come back after treatment or has spread to other parts of the body.

One way regorafenib might inhibit tumor growth is by interfering with the growth of the blood vessels that tumors need to receive nutrients and to spread. The drug is already approved for treating metastatic colorectal cancer and gastrointestinal stromal tumor, but its use in this study is considered investigational. Regorafenib is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

Patients must have adenoid cystic carcinoma that has come back after treatment or has spread to other parts of the body and cannot be cured with surgery or radiation therapy.

At least 2 weeks must have passed since completion of prior therapies (4 weeks for bevacizumab) and entry into the study.

There must be evidence that the cancer is growing or causing patients to have symptoms.

Patients may not have previously received regorafenib.

Patients must be able to be walk and do routine activities for more than half of their normal waking hours.

This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alan L. Ho at 646-888-4235.